Clinical Report: A Comparative Analysis of Clinical Variations in TCM Patterns for UC

Overview

This study investigates the clinical differences between two Traditional Chinese Medicine (TCM) patterns in ulcerative colitis (UC): dampness-heat in the large intestine (DCSR) and spleen deficiency with dampness accumulation (PXSY).

Background

Ulcerative Colitis (UC) is a chronic autoimmune disease with rising incidence, particularly in Asia. Traditional Chinese Medicine (TCM) employs pattern differentiation as a therapeutic approach.

Data Highlights

Key Findings

• Patients with DCSR pattern showed significantly higher inflammatory markers compared to PXSY.
• DCSR patients exhibited more severe endoscopic inflammation with higher scores.
• Ulcer formation was identified as an independent differentiating factor between DCSR and PXSY patterns.
• Histological analysis revealed more severe mucosal damage in the DCSR group.
• Higher expression levels of NOX2, CD11b, and NETs were observed in DCSR patients.

Clinical Implications

Understanding these patterns may enhance the management of UC.

Conclusion

The study highlights significant clinical differences between the DCSR and PXSY patterns in UC.

Related Resources & Content

1. Evaluating Anorectal Function in Individuals with Recurrent Ulcerative Colitis, Journal of Gastroenterology, 2024 -- https://link.springer.com/article/10.1007/s00384-024-04680-1
2. Traditional Chinese medicine syndrome patterns and associated factors in adults with type 2 diabetes and metabolic syndrome: a data-driven analysis, Frontiers in Endocrinology, 2026 -- https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1843491/full
3. Endoscopic Brush Sample Analysis Reveals Mucosal Dysbiosis in Patients with Inflammatory Bowel Disease, Journal of Gastroenterology, 2017 -- https://link.springer.com/article/10.1007/s00535-017-1384-4
4. Comparative Analysis of Clinical Phenotypes in Familial versus Sporadic Crohn’s Disease in Eastern China
5. Updated ACG Guidelines for Ulcerative Colitis Management, American College of Gastroenterology, 2025
6. Living Guideline for Pharmacological Management of Moderate-to-Severe Ulcerative Colitis, American Gastroenterological Association, 2026
7. https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617
8. New ECCO Guidelines on Opportunistic Infections in IBD – 2025 Update - ECCO - European Crohn’s and Colitis Organisation
9. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial - PubMed
10. DOP002 Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE) | Journal of Crohn's and Colitis | Oxford Academic
11. P0593 Impact of up to 3 years of continuous etrasimod treatment: Long-term efficacy results from the ELEVATE UC open-label extension | Journal of Crohn's and Colitis | Oxford Academic
12. Frontiers | Systematic review and network meta-analysis of integrated traditional Chinese and conventional medicine for ulcerative colitis
13. Efficacy and safety of oral traditional chinese medicine in maintaining remission of ulcerative colitis: Meta-analysis - ScienceDirect
14. Frontiers | A Comparative Study on the Clinical Differences in Traditional Chinese Medicine Pattern in Ulcerative Colitis Utilizing Multidimensional Data